Published in AIDS Weekly, January 24th, 2005
The company expects fourth-quarter net revenue will exceed $1.1 million and that gross margins will exceed 40%. As a result, the company expects total net revenues increasing in 2004 over 2003 by at least 15%, despite significantly reduced revenue from noncore and discontinued products of about $700,000.
Lawrence A. Siebert, Chembio's president, commented, "These results demonstrate that our shift from...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.